Journal article icon

Journal article

A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098

Abstract:

Background

GSK2256098 is a novel oral focal adhesion kinase (FAK) inhibitor. Preclinical studies demonstrate growth inhibition in glioblastoma cell lines. However, rodent studies indicate limited blood–brain barrier (BBB) penetration. In this expansion cohort within a phase I study, the safety, tolerability, pharmacokinetics (PK), and clinical activity of GSK2256098 were evaluated in patients with recurrent glioblastoma. Biodistribution and kinetics of [11C]GSK2256098 were assess...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1093/neuonc/noy078

Authors


Expand authors...
Publisher:
Oxford University Press Publisher's website
Journal:
Neuro-Oncology Journal website
Volume:
20
Issue:
12
Pages:
1634-1642
Publication date:
2018-05-17
Acceptance date:
2018-05-08
DOI:
EISSN:
1523-5866
ISSN:
1522-8517
Pubs id:
pubs:854633
URN:
uri:ba79490e-dcd2-4f4b-a6cb-8ca34931b307
UUID:
uuid:ba79490e-dcd2-4f4b-a6cb-8ca34931b307
Local pid:
pubs:854633

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP